4D Molecular Therapeutics (NASDAQ:FDMT) PT Raised to $40.00 at Royal Bank of Canada

4D Molecular Therapeutics (NASDAQ:FDMT) had its price objective upped by Royal Bank of Canada from $35.00 to $40.00 in a research note released on Monday, Benzinga reports. The brokerage currently has an outperform rating on the stock.

A number of other brokerages have also issued reports on FDMT. Jefferies Financial Group boosted their target price on shares of 4D Molecular Therapeutics from $30.00 to $58.00 and gave the stock a buy rating in a research report on Monday, April 1st. The Goldman Sachs Group reaffirmed a buy rating and set a $81.00 target price on shares of 4D Molecular Therapeutics in a research report on Wednesday, February 7th. Barclays initiated coverage on shares of 4D Molecular Therapeutics in a research report on Monday. They set an overweight rating on the stock. BMO Capital Markets lowered their price objective on 4D Molecular Therapeutics from $70.00 to $63.00 and set an outperform rating on the stock in a research report on Monday, April 1st. Finally, HC Wainwright reiterated a buy rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Friday, March 1st. Ten research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of Buy and an average price target of $44.22.

4D Molecular Therapeutics Trading Down 0.4 %

Shares of NASDAQ:FDMT opened at $26.25 on Monday. The stock has a market capitalization of $1.34 billion, a PE ratio of -9.87 and a beta of 2.87. 4D Molecular Therapeutics has a 1 year low of $9.44 and a 1 year high of $36.25. The firm has a fifty day moving average price of $29.20 and a 200 day moving average price of $19.96.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings data on Thursday, February 29th. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.09). 4D Molecular Therapeutics had a negative return on equity of 34.14% and a negative net margin of 436.30%. The business had revenue of ($0.02) million for the quarter, compared to analyst estimates of $4.67 million. On average, sell-side analysts forecast that 4D Molecular Therapeutics will post -3.03 earnings per share for the current fiscal year.

Insider Transactions at 4D Molecular Therapeutics

In related news, insider Scott Bizily sold 8,153 shares of 4D Molecular Therapeutics stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $31.78, for a total transaction of $259,102.34. Following the completion of the transaction, the insider now directly owns 1,737 shares of the company’s stock, valued at approximately $55,201.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Scott Bizily sold 8,153 shares of the firm’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $31.78, for a total transaction of $259,102.34. Following the completion of the sale, the insider now directly owns 1,737 shares of the company’s stock, valued at approximately $55,201.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO David Kirn sold 5,696 shares of the business’s stock in a transaction on Tuesday, January 23rd. The stock was sold at an average price of $18.41, for a total value of $104,863.36. Following the completion of the transaction, the chief executive officer now directly owns 1,151,154 shares in the company, valued at approximately $21,192,745.14. The disclosure for this sale can be found here. In the last quarter, insiders have sold 147,888 shares of company stock valued at $4,134,254. 10.70% of the stock is owned by insiders.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bfsg LLC bought a new stake in shares of 4D Molecular Therapeutics during the fourth quarter valued at approximately $30,000. International Assets Investment Management LLC bought a new position in 4D Molecular Therapeutics in the 3rd quarter valued at $36,000. US Bancorp DE increased its stake in shares of 4D Molecular Therapeutics by 580.7% in the 4th quarter. US Bancorp DE now owns 1,797 shares of the company’s stock valued at $36,000 after buying an additional 1,533 shares during the period. Lazard Asset Management LLC boosted its stake in 4D Molecular Therapeutics by 44.2% in the second quarter. Lazard Asset Management LLC now owns 2,190 shares of the company’s stock valued at $38,000 after acquiring an additional 671 shares during the last quarter. Finally, Ensign Peak Advisors Inc grew its holdings in 4D Molecular Therapeutics by 167.9% during the 3rd quarter. Ensign Peak Advisors Inc now owns 7,180 shares of the company’s stock worth $58,000 after acquiring an additional 4,500 shares during the period. Institutional investors and hedge funds own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.